NOV 17, European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax' COVID-19 vaccine. Here is a summary of NVAX EMA review process and current status. [Process] 1. Rolling reveiw (Several rolling review cycles can be done) - NVAX : data submission to EMA - EMA : evaluate data for promising medicine as soon as possible (to ..
